G astroesophageal reflux disease (GERD), a condition characterized by symptoms of heartburn and acid regurgitation, occurs in approximately 7% of the adult population on a daily basis, 14-20% on a weekly basis, and 36-44% on a monthly basis. [1] [2] [3] Natural history studies indicate that patients with GERD suffer a chronic, relapsing course of disease, regardless of the presence or absence of esophagitis, with at least 50% of patients remaining on continuous medical therapy at year 3 of follow-up. 4, 5 The chronicity of symptoms and the availability of effective medical therapy have resulted in substantial utilization of health care resources. In fact, antisecretory agents, such as histamine H 2 -receptor antagonists, may account for 7-10% of a managed care pharmacy's budget, while sales of proton-pump inhibitors increased by 46% and 31% in 1996 and 1997, respectively. a Yet, despite rising expenditures and high utilization by patients with GERD, only about 24% Abstract: The ability of various strategies to identify patients with gastroesophageal reflux disease (GERD) and the relative economic impact on disease management programs for GERD were studied.
A telephone interview was conducted of a random sample of patients enrolled in any of three health plans in a 100,000member managed care organization who had either a pharmacy claim or an encounter claim during 1997. The telephone interview identified patients with GERD and served as the standard by which the sensitivity, specificity, and predictive values of the following patient-identification strategies were compared: (1) telephone interview, (2) chart review, (3) use of encounter claims, (4) use of pharmacy claims, (5) use of both encounter claims, and pharmacy claims, and (6) use of encounter claims or pharmacy claims. Conservative estimates of costs and projected savings were then used to model the potential return on investment of the strategies.
A total of 1186 patients completed the telephone interview, of whom 390 (33%) met the case definition of GERD. The most sensitive method for identifying patients with GERD was using either pharmacy or encounter claims (26%). The most specific strategy with the highest positive predic-tive value (PPV) (87%) was using both pharmacy and encounter claims, but this approach had a case-detection rate of only 3%. Encounter claims were significantly more sensitive than pharmacy claims and yielded a higher estimate of prevalence. The telephone interview identified the most subjects who could have benefited from a disease management program and cost 84% less than chart review. While use of administrative data (pharmacy and encounter claims) was the least costly strategy, it identified 74% fewer patients expected to benefit from disease management.
The efficiency of disease management programs for GERD may depend on the method of patient identification, which in turn may depend on whether PPV or negative predictive value (NPV) should be maximized. If there is a need to identify all cases (i.e., sensitivity and NPV are most important), then telephone interview may provide the greatest opportunity for disease management with the greatest return on investment, but at the expense of enrolling many patients who may not benefit.
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identify patients with GERD, and (3) to understand the costs and opportunities for disease management when patients are identified by the different strategies.
Methods
The study site was a 100,000member medical-group-model managed care organization in southern California. The study was performed between April 1998 and April 1999. Strategies evaluated for identifying patients with GERD included telephone interview with a validated GERD questionnaire, 11 chart review, and analysis of administrative claims data from three health plans. Two sources of claims data were considered: claims for prescription medications (referred to as pharmacy claims) and claims for medical professional office visits (referred to as encounter claims). The three plans were selected because they cover approximately 80% of the medical group's managed care patients.
Approval was obtained from the medical group. All patients in each of three health plans who had been continuously enrolled for more than six months were randomized for telephone interviews by using a randomnumber generator. The telephone interview comprised five domains and included questions from a validated questionnaire for the identification of patients with GERD (Table 1) . 11 If the interviewers could not contact a patient within five attempts (with each attempt made in the evening of a different day), that patient was eliminated from the sample. Patients were determined to have GERD if (1) they qualified on the basis of the validated-questionnaire component of the interview (the scoring was amended to allow for patients reporting symptoms less than weekly but more than twice monthly), (2) a physician had told them that they had GERD or esophagitis, (3) they had reported heartburn or regurgitation within the past month and had of patients with monthly symptoms of more than three months' duration access the medical care delivery system by consulting a physician. 6 In addition, patients with GERD report greater impairment of quality of life than patients with peptic ulcer disease, angina, mild congestive heart failure, or menopause. 7 Appropriate management of GERD results in significant improvements in quality of life.
Disease, or population, management represents a potentially effective strategy for addressing the issues raised by GERD in managed care environments. Disease management may be defined as an approach to patient care that uses evidence-based principles to provide high-quality care to populations of patients across the entire delivery system and the continuum of care. 8 A critical aspect of disease management involves patient identification-whether of patients with a condition or specific groups of high-risk patients.
The traditional standards for diagnosing GERD include ambulatory 24-hour esophageal pH monitoring and upper-gastrointestinal-tract endoscopy. However, because of the limitations of these tests, GERD is now considered a clinical diagnosis. 9 Also, the limitations of administrative data make patient identification and selection difficult in that laborious chart review or patient interview may be necessary. 10 The expense associated with chart review may limit the use of this approach.
Since GERD is a disorder for which many patients do not see a physician and is often not the primary patient complaint, we hypothesized that using administrative claims data may be an insensitive method for identifying patients who may benefit from a disease management program for GERD. The purpose of this study was (1) to estimate the prevalence of GERD in a large managed care organization, (2) to test the ability of various strategies to taken nonprescription or prescription medications for their symptoms at least weekly, or (4) they had undergone endoscopy or an esophageal pH test with abnormal findings suggestive of GERD. Since uppergastrointestinal-tract endoscopy and ambulatory 24-hour pH monitoring were not used as enrollment criteria in the study, it was not known whether patients had erosive or nonerosive GERD (unless there was a record of the test result). A panel of two physicians and one pharmacist was used to reach consensus in categorizing patients for whom data were missing or interviewing was inconclusive. Efforts to contact patients continued until approximately 400 patients with GERD were identified through telephone interview.
The study was conducted in two phases. Phase 1 was designed to estimate the overall prevalence of GERD in our medical group population by using telephone interview and chart abstraction. The sample consisted of adult (age, >18 years) medical-group patients who were enrolled in any of the three health plans during 1997 and who had a telephone number on file. Phase 2 compared the ability of alternative methods (telephone interview, chart review, and use of administrative claims data) to identify patients with GERD. Phase 2 patients had to meet the same criteria as phase 1 patients, except that they also had to have utilized a medical service, as indicated by a pharmacy claim, an encounter claim, or both.
A structured chart-abstraction instrument and medical-record-based criteria for identifying patients with GERD were developed by a team composed of a pharmacist, an internist, a gastroenterologist, and a nurse with experience in abstracting charts. The chart abstraction included collecting information on GERD symptom frequency and severity, medication use, referrals, and procedures. Chart abstraction was performed by trained nurse abstracters blinded to the identification strategy and the presumptive diagnosis. The abstraction instrument was revised on the basis of feedback after one round of pilot testing. In phase 1, chart abstraction was performed for random samples of 100 patients whose telephone interview indicated no symptoms of GERD and 100 patients whose telephone interview indicated GERD symptoms. Patients were identified as having GERD if any of the following descriptive terms was documented in a primary care or specialist progress note or problem list during 1997: heartburn, acid regurgitation, GERD, acid reflux, acid dyspepsia, water brash, esophagitis, indigestion, hyperacidity, dysphagia, reflux laryngitis, Barrett's esophagus, or esophagospasm or reflux-induced cough or asthma; if the patient was taking any GERD-related medication b ; if an endoscopy report suggested a gastroesophageal reflux-related condition; if there was documented esophagitis; or if an esophageal pH test result was abnormal.
Two sources of claims data were available for phase 2. Pharmacy claims files were obtained from three health plans for the 1997 calendar year. For two of the three plans, data were available for only the third and fourth quarters. These files contained information on any prescribed drugs charged to the health plan. The pharmacy claims files from the health plans were combined with administrative data files containing encounter claims. A relational data-base (Microsoft Access, Microsoft, Redmond, WA) was used to integrate the two claims databases, with the patient's social security number used as the unique identifier. Patients were identified as having GERD if certain International Classification of Diseases (ICD-9) encounter codes were found in the claims data (Table 2 ) or if they had filled a prescription for a GERD-related medication. b The sensitivity and specificity of each method of patient identification were calculated by using the telephone interview as the standard. Sensitivity was defined as the number of patients identified by chart review (or administrative claims data) divided by the number of patients who had GERD identified by telephone interview (the truepositive rate). Specificity was defined as the number of patients who did not have GERD identified by chart review (or administrative claims data) divided by the number of patients who did not have GERD identified by telephone interview (the true-negative rate). The positive predictive value (PPV) was calculated by dividing the number of true positives by the number of all positive results, and the negative predictive value (NPV) was calculated by dividing the number of true negatives by the number of all negative results. McNemar's test was performed to determine whether there were significant differences among the strategies.
A cost-comparison model was developed to project the relative cost associated with identifying eligible patients by each strategy (Microsoft Excel). This model incorporated the medical-group direct costs associated with each strategy (Table 3) , the prevalence of GERD, the characteristics of each test, the telephone survey response rates, and the predictive values for each strategy (i.e., the number of patients identified). Once the number of true positives was calculated, we applied the cost for each identification strategy and derived the cost per correctly identified patient.
Results
In phase 1, a total of 362 (83%) of 436 patients randomly selected from those enrolled in any of the three health plans answered the questionnaire by telephone. One hundred nine patients (30%) met the criteria for GERD, and 193 (53%) did not. Therefore, with the telephone interview used as the diagnostic standard for GERD, the prevalence of GERD in this population was 30%.
For the 109 patients identified by telephone interview as having GERD, we located and abstracted 87 patient medical records; of these, 16 (18%) met the criteria for GERD. Of the patients who were GERD negative by telephone interview, we attempted to abstract 100 charts but stopped when not one chart-positive patient was identified after 70 charts were reviewed. Thus, for the 157 charts ab- Table 1 .
Domains of Questionnaire Used in Telephone Interview

Domain Example No. Items
Previous diagnosis
Typical and atypical symptoms of GERD b
Frequency of GERD symptoms Use of GERD-related lifestyle modification and pharmacotherapy GERD-related utilization of medical services Has a doctor ever told you that you have GERD, a esophagitis, or acid reflux disease? Have you had heartburn (a rising, spreading, uncomfortable feeling behind your breastbone)? Do you have symptoms daily, weekly, or monthly? Do you take antacids for heartburn? How frequently?
Have you ever been referred to a gastroenterologist (specialist)? Symptoms were based on a validated questionnaire about GERD. 11 stracted, the estimated prevalence of GERD was 10%. With the telephone interview used as the standard, chart review was 100% specific (95% confidence interval [CI], 95-100%) but only 18% sen-sitive (95% CI, 10-26%) for detecting patients with GERD (Table  4 ). The PPV (95% CI) and the NPV (95% CI) for chart review were 100% (95-100%) and 50% (42-57%), respectively.
In phase 2, we randomly sampled a population of patients who had a pharmacy or encounter claim in 1997 to determine the relative accuracy of chart review and administrative claims for identifying patients Table 2 . Based on projected identification of all patients with GERD in a 100,000-member medical-group-model managed care organization in southern California. Table 4 . with GERD. In phase 2, 1186 of 1700 patients participated in telephone interviews (70% response rate), and 390 (33%) of them had GERD. As expected, some patients had only pharmacy claims or only encounter claims. There were 563 unique encounter claims and 852 unique pharmacy claims. The sensitivity and specificity of chart review and claims data are presented in Table 5 . The most sensitive strategy for identifying patients with GERD appeared to be using either pharmacy or encounter claims (26%; 95% CI, 22-30%), but this strategy had a PPV of only 58% (95% CI, 51-72%). The most specific strategy, and the one with the highest PPV (87%; 95% CI, 70-100%), included selecting patients with both pharmacy and encounter claims, but this strategy had poor sensitivity and a case detection rate of only 3% (95% CI, 1-5%). Encounter claims alone were more sensitive than pharmacy claims alone (p < 0.01), but pharmacy claims were more specific (p < 0.01).
International Classification of Diseases Codes Used to Identify Patients with Gastroesophageal Reflux Disease (GERD)
Projected Costs of Strategies for Identifying Patients with Gastroesophageal Reflux Disease (GERD)
Strategy
Number of Patients with Gastroesophageal Reflux Disease (GERD) Identified through Chart Review
Result of Chart Review
Positive for GERD by Telephone Interview
Negative for GERD by Telephone Interview Total
While the results of chart review for phase 2 may have been confounded by the small number of charts reviewed, the sensitivity was 28% (95% CI, 23-33%), similar to the sensitivity of using pharmacy or encounter claims (Table 5 ). While chart review had the highest PPV (100%; 95% CI, 91-100%), it had the lowest NPV (16%; 95% CI, 12-19%), and it required the most personnel, time, and expense.
The preceding analysis allowed the prevalence of GERD to be estimated by alternative strategies. Irrespective of the denominator used (phase 1 or phase 2), the telephone interview provided an estimated prevalence of approximately 30%. With a denominator of patients enrolled in one of the three health plans (the denominator in phase 1), chart review estimated the GERD prevalence to be 10%. With a denominator of enrolled patients who had an encounter or pharmacy claim (the de-nominator in phase 2), the prevalence of GERD estimated by combining encounter claims and pharmacy claims was 15%, compared with 12% for encounter claims alone and 5% for pharmacy claims alone.
We estimated the return on investment of disease management programs for GERD by using the cost-comparison model and the predictive values for each strategy ( Table  6 ). The telephone survey identified the most patients expected to benefit from a disease management program for GERD, with a cost of $24.69 per patient. This represented an 84% cost saving compared with chart review. While the most efficient use of administrative data appeared to involve encounter or pharmacy claims ($0.06 per correctly identified patient), this strategy identified 74% fewer patients expected to benefit from a disease management program than did telephone interviews (Table 6 ).
Discussion
Disease management presents an opportunity to use evidence-based principles to manage patients with chronic conditions across the continuum of care. A critical feature of disease management in integrated health systems is the accurate and efficient identification of eligible patients. 8 In organizations with integrated information systems, administrative claims data offer an efficient mechanism for patient identification. For certain chronic medical conditions, however, diagnostic and coding difficulties may thwart even sophisticated information systems. The upper-gastrointestinal-tract disorders, such as GERD, represent a unique challenge to using administrative data because of the tremendous overlap in symptom patterns with other diseases, the existence of antiquated and confusing terminology (such as "reflux-like dyspepsia"), the relevant ICD-9 codes that represent symptoms rather than diagnoses, and the frequent self-management of GERD with nonprescription medications. The results of this analysis suggest that the strategy used to identify patients with GERD may significantly influence the cost and effectiveness of a disease management program. Therefore, the identification strategy that will yield the most eligible patients for the program, with the appropriate balance of economic efficiency, sensitivity, and specificity, becomes critical to maximizing the potential impact of the program.
Our analysis suggests that using administrative data, particularly a combination of encounter and pharmacy claims, may be an efficient approach to identifying patients with GERD. However, this strategy identified 43% fewer patients expected to benefit than chart review and 74% fewer than a telephone survey. Thus, if the organizational objective is to improve health in the greatest proportion of eligible patients, then a telephone survey may be the preferred approach. At a cost of approximately $25 per correctly identified patient, a telephone survey may provide an optimal balance between accuracy and efficiency, depending on the cost of the disease management program itself and the cost savings realized by the organization. The decision may ultimately depend on the perceived or demonstrated value of the disease management program. If the program results in significant improvements in health and economic outcomes, then the cost-to-benefit ratio may favor the identification strategy that is less efficient but identifies the largest proportion of eligible patients. If the program results in modest improvements in outcomes, then the most efficient strategy may be most appropriate. Finally, since patients with long-standing GERD are at risk of developing Barrett's esophagus and esophageal adenocarcinoma, 12, 13 decision-makers may want to implement the strategy that identifies the greatest proportion of inadequately managed patients.
Our study has several limitations. First, while the telephone survey is based on a validated instrument in a referral population, it has not been validated in a primary care population. Second, since the diagnostic standard for GERD is ambulatory 24-hour pH monitoring or uppergastrointestinal-tract endoscopy or both, our test characteristics may not be accurate, since we used the telephone survey as the diagnostic standard. However, for practical purposes, GERD is considered a clinical diagnosis, and patient report of symptoms is an accepted method of diagnosis. 14 Also, since we could not perform chart review and claims data analysis for all subjects surveyed by telephone, the results may be confounded by unknown bias in the sample. Moreover, pharmacy claims data have inherent limitations, because many GERD patients selfmanage their symptoms with non-prescription medications (including histamine H 2 -receptor antagonists) and do not generate pharmacy or encounter claims. Indeed, that encounter claims were more sensitive than pharmacy claims suggests this. Finally, our projections are based on patients in our medical group and may not be generalizable to other practice settings.
Conclusion
The efficiency of disease management programs for GERD may depend on the method of patient identification, which in turn may depend on whether PPV or NPV should be maximized. If there is a need to identify all cases (i.e., sensitivity and NPV are most important), then telephone interview may provide the greatest opportunity for disease management with the greatest return on investment, but at the expense of enrolling many patients who may not benefit. a Data on file. IMSAmerica,Westport, CT; 1997. b The GERD-related prescription medications are sucralfate, metoclopramide, cisapride, cimetidine, ranitidine, famotidine, nizatidine, omeprazole, and lansoprazole. a Based on projected costs for a 100,000-member medical-group-model managed care organization in southern California. b Assumes searchable electronic databases of merged encounter and pharmacy claims data. c Assumes a positive predictive value of 0.90 for the telephone survey instead of 1.0 (i.e., the standard).
